ArticleBMJ open ophthalmology2020

Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy.

Paul F Kenna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.